Jiang Peng, Chu Mingfei, Liang Yu
Department of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, China.
J Cell Mol Med. 2025 Jan;29(2):e70376. doi: 10.1111/jcmm.70376.
Accumulating research indicates that N6-methyladenosine (m6A) modification plays a pivotal role in colorectal cancer (CRC). Hence, investigating the m6A-related long noncoding RNAs (lncRNAs) significantly improves therapeutic strategies and prognostic assessments. This study aimed to develop and validate a prognostic model based on m6A-related lncRNAs to improve the prediction of clinical outcomes and identify potential immunological mechanisms in CRC. We obtained high-throughput CRC data from The Cancer Genome Atlas to identify a prognostic model based on m6A-related lncRNAs. Then, the model was constructed and validated through LASSO analysis and Cox regression using R software. The clinical applicability was enhanced by developing a nomogram. We further conducted experiments to reveal the biological function of LINC00543. The prognostic model based on eight m6A-related lncRNAs exhibited impressive accuracy, achieving an area under the receiver-operating curve value of 0.753, 0.682 and 0.706 for predictions after 1, 3 and 5 years, respectively. The Kaplan-Meier analysis confirmed the consistency of the model across different pathological characteristics, with a high-risk group showing a poorer prognosis. Furthermore, the model was linked to immune function, particularly the type I interferon response, through gene set enrichment analysis and experimental validation. Our study presented a m6A-related lncRNA prognostic model for CRC with potential clinical utility. The model not only provided improved accuracy over traditional staging but also offered insights into the immunological mechanisms of CRC, facilitating personalised medicine approaches.
越来越多的研究表明，N6-甲基腺苷（m6A）修饰在结直肠癌（CRC）中起着关键作用。因此，研究与m6A相关的长链非编码RNA（lncRNA）可显著改善治疗策略和预后评估。本研究旨在开发并验证一种基于m6A相关lncRNA的预后模型，以改善临床结局预测并确定CRC中的潜在免疫机制。我们从癌症基因组图谱获取了高通量CRC数据，以识别基于m6A相关lncRNA的预后模型。然后，使用R软件通过LASSO分析和Cox回归构建并验证该模型。通过绘制列线图提高了临床适用性。我们进一步开展实验以揭示LINC00543的生物学功能。基于8种m6A相关lncRNA的预后模型表现出令人印象深刻的准确性，在1年、3年和5年预测时的受试者工作特征曲线下面积值分别为0.753、0.682和0.706。Kaplan-Meier分析证实该模型在不同病理特征中的一致性，高危组预后较差。此外，通过基因集富集分析和实验验证，该模型与免疫功能相关，特别是I型干扰素反应。我们的研究提出了一种具有潜在临床应用价值的CRC的m6A相关lncRNA预后模型。该模型不仅比传统分期提供了更高的准确性，还为CRC的免疫机制提供了见解，有助于个性化医疗方法。
